Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425945 · ClinicalTrials.gov registry record · NA
Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 130
- Enrollment target
NCT00425945: Completed NA study, sponsored by Stanford University.
NCT00425945 is a NA study that has completed, run by Stanford University. The registered enrollment target is 130 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00425945, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 130 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, in lowering blood pressure and improving glycemic control and plasma lipoprotein profile.
Interventions
- DRUG Pine Bark Extract (Flavangenol®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00425945
The ClinicalTrials.gov registry entry for NCT00425945 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pine Bark Extract (Flavangenol®) is the first listed.
NCT00425945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00425945 about?
NCT00425945 is a clinical study titled "Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study". The purpose of this study is to investigate the efficacy of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, in lowering blood pressure and improving glycemic control and plasma lipoprotein profile.
What is the current status of trial NCT00425945?
This trial is currently completed. It is a NA study. The enrollment target is 130 participants. The study started on 2006-10. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00425945?
The interventions under investigation include: Pine Bark Extract (Flavangenol®) (DRUG).
Who is sponsoring clinical trial NCT00425945?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.